Utilizing AI systems like AlphaFold 3 to predict 3D molecular structures and accelerate clinical trials. Biotech firms are halving discovery timelines and cutti
AI drug discovery spans target identification (foundation models over biology), molecule generation and property prediction, protein structure (AlphaFold lineage), and clinical-trial optimization: compressing the famously slow, expensive pharma funnel. By 2026 dozens of AI-originated candidates sit in clinical stages, and every major pharma runs AI-native discovery programs or partnerships.
Biology resists shortcuts: models propose, but wet-lab truth disposes, and overhyped in-silico claims have burned credibility. Programs that compound pair every prediction with rapid experimental validation, invest in proprietary data generation, and respect that clinical risk, not discovery speed, still dominates pharma economics.
AI-discovered candidates have reached late clinical stages with the first approvals emerging; more decisively, AI is now embedded across discovery at every major pharma: the question shifted from 'if' to 'how much of the funnel'.
Early phases (target-to-candidate) compress dramatically, months instead of years in documented cases, while clinical phases remain the long pole. Net effect: more shots on goal per dollar, not instant drugs.